Loading
Loading
Research Overview
Single-molecule dual GLP-1R and amylin receptor co-agonist; integrates GLP-1-mediated appetite suppression and insulin sensitisation with amylin-mediated brainstem and hypothalamic satiety signalling in a single molecular entity.
Overview
Amycretin combines GLP-1 receptor agonism and amylin receptor agonism (AMY1-3) within a single molecular scaffold, eliminating the need for separate semaglutide and cagrilintide injections. The compound is under investigation in both subcutaneous (once-weekly) and oral (once-daily) formulations, with Phase 1/2 data providing early evidence for efficacy and tolerability.
The dual mechanism engages two complementary appetite-suppression pathways: GLP-1 receptor-mediated reduction of food intake and delayed gastric emptying, combined with amylin receptor-mediated satiety signalling in the brainstem and hypothalamus. Early trial data from the CagriSema programme (separate cagrilintide + semaglutide injection) has demonstrated approximately 25% weight loss with dual activation — amycretin aims to deliver comparable efficacy in a single agent.
Amycretin's early Phase 1/2 weight-loss data has been notable, with dose-escalation studies reporting weight reductions that appear to exceed semaglutide monotherapy benchmarks — consistent with the additive effect hypothesis from the CagriSema data. GI tolerability was reportedly milder than semaglutide alone, potentially enabling higher combined doses.
Compliance
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, amycretin has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Pharmacology
Single-molecule dual GLP-1R and amylin receptor co-agonist; integrates GLP-1-mediated appetite suppression and insulin sensitisation with amylin-mediated brainstem and hypothalamic satiety signalling in a single molecular entity.
Support
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.